₹1123.0
-1.54% today
· 30d +1.77%
as of 2026-09-04
Price · Daily Candles
“Zydus Life Sciences: DIIs increase stake as Q4 profits grow, stock nears 52-week high.”
Zydus Life Sciences reports a strong Q4 2026, with revenue growing 16.22% YoY to ₹7587 Cr and net profit increasing 7.82% YoY to ₹1341 Cr. For the full fiscal year 2026, annual revenue rose 16.81% and net profit increased 9.65%. The stock is trading at a P/E of 21.53, with a ROCE of 21.0%, while DIIs increased their stake by 0.11% QoQ to 11.2%.
BULL CASE
+Q4 2026 revenue increased by 16.22% YoY to ₹7587 Cr, demonstrating robust sales growth.
+Annual revenue for FY2026 grew by 16.81% YoY to ₹27148 Cr, alongside a 9.65% increase in net profit to ₹5124 Cr.
+Operating profit for Q4 2026 surged by 21.87% YoY to ₹2689 Cr, with an OPM of 34.82%.
+Company’s 3-year revenue CAGR stands at 15.93% and net profit CAGR at 37.75%.
+DII shareholding increased by 0.11% QoQ, reflecting increased domestic institutional confidence, holding 11.2% as of Q4 2026.
BEAR CASE
−Despite growth, Q4 2026 net profit growth of 7.82% YoY lagged behind revenue growth of 16.22%.
−FII shareholding decreased by 0.11% QoQ, with current holdings at 6.95%.
−While nearing 52-week highs, the stock is currently trading at a P/E of 21.53, higher than nearest peer DRREDDY at 19.55.
−The trailing twelve-month Free Cash Flow is negative at -₹1277 Cr, resulting in a negative FCF yield of -1.18%.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-06-30
REVENUE
₹8017 Cr
+21.96% YoY
NET PROFIT
₹990 Cr
-34.9% YoY
OPM
25.06%
-8.28pp YoY
EPS
₹9.35
PE 21.53
Intrinsic value · DCF: N/A — Company is currently free-cash-flow negative (-1.1% of mktcap). DCF assumes a going concern generating positive cash flow; a meaningful intrinsic value can only be computed once FCF turns positive. Use the Strategy Fit and ML sections instead.
◇ Sector Position
Zydus Life Sciences with a P/E of 21.53 and ROCE of 21.0% appears favorably positioned compared to peers like SUNPHARMA (PE 40.41, ROCE 22.46%) and DIVISLAB (PE 69.81, ROCE 21.47%), but registers a lower ROCE than sector leader DRREDDY (ROCE 27.63%).
PEERPEROCE %
ZYDUSLIFE21.5321.0
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒
72
SCORE / 100
Overall
6-axis composite of the sections below.
Performance
STRONG
75
Valuation
REASONABLE
60
Growth
STRONG
73
Profitability
HIGH
92
Technicals
NEUTRAL
55
Risk
LOW
80
Key Stats
TTM PE
21.53
P/B
4.29
52W HIGH
₹1205.0
OFF HIGH
-6.8%
DIV YIELD
0.09%
MKT CAP
₹113153 Cr
◉ Active Signals
MACDNeutral-1.3146
RSI(14)Neutral45.85
Street Consensus
30 analysts₹1066.5
mean target
Low ₹800.0Now ₹1123.0High ₹1457.0
⧉ Strategy Fit 🔒